Cocrystal Pharma Files 8-K
Ticker: COCP · Form: 8-K · Filed: Mar 19, 2024 · CIK: 1412486
| Field | Detail |
|---|---|
| Company | Cocrystal Pharma, INC. (COCP) |
| Form Type | 8-K |
| Filed Date | Mar 19, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, reporting
TL;DR
Cocrystal Pharma filed a routine 8-K, no major news.
AI Summary
Cocrystal Pharma, Inc. filed an 8-K on March 19, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates routine corporate reporting by Cocrystal Pharma, Inc. to the SEC, without disclosing new material events.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting purposes and does not contain any new material information that would significantly impact the company's risk profile.
Key Players & Entities
- Cocrystal Pharma, Inc. (company) — Registrant
- BIOZONE PHARMACEUTICALS, INC. (company) — Former company name
- International Surf Resorts, Inc. (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing for Cocrystal Pharma, Inc.?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits, as indicated by the filing's item information.
When was this 8-K report filed with the SEC?
This 8-K report was filed with the SEC on March 19, 2024.
What is the principal executive office address for Cocrystal Pharma, Inc.?
The principal executive office address for Cocrystal Pharma, Inc. is 19805 N. Creek Parkway, Bothell, WA 98011.
What is Cocrystal Pharma, Inc.'s state of incorporation?
Cocrystal Pharma, Inc. is incorporated in Delaware.
Has Cocrystal Pharma, Inc. had previous company names?
Yes, Cocrystal Pharma, Inc. was formerly known as BIOZONE PHARMACEUTICALS, INC. and International Surf Resorts, Inc.
Filing Stats: 437 words · 2 min read · ~1 pages · Grade level 10.4 · Accepted 2024-03-19 08:30:27
Filing Documents
- form8-k.htm (8-K) — 38KB
- ex99-1.htm (EX-99.1) — 16KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001493152-24-010426.txt ( ) — 232KB
- cocp-20240319.xsd (EX-101.SCH) — 3KB
- cocp-20240319_lab.xml (EX-101.LAB) — 33KB
- cocp-20240319_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 19, 2024 Cocrystal Pharma, Inc. By: /s/ James Martin Name: James Martin Title: Chief Financial Officer and Co-Chief Executive Officer